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Abstract 
Objective: Thalidomide is a potent inhibitor of angiogenesis. We evaluated the effects of Thalidomide
on comeal angiogenesis and on tissue survival of grafts in rabbit eyes with pre-existing
neovascularization secondary to alkali bum.
Methods: Sixteen rabbits received alkali bums to one cornea. One month post-injury, assessments of
comeal neovascularization were performed followed by corneal transplantation. Four rabbits received
oral Thalidomide and ten got placebo (powdered sugar) for thirty days. Total comeal neovascularization
(NV), clock hours (CH) involved in (NV), longest (NV) pedicle length (NVP) and the duration of time
required for NV to develop were assessed.
Results: Thalidomide significantly decreased the total neovascularization (p<0.0072), the number
of(CH) involved (p<0.0002) and the longest (NVP) length (p<0.0001). There was also a significant
delay in the earliest development of NV in the test group (p<0.0064). The test group retained comeal
clarity significantly longer than the control group (p< 0.0008).
Conclusion: Thalidomide is an effective inhibitor of corneal angiogenesis and prolongs graft survival
as measured by graft clarity in donor corneas in eyes with previous neovascularization secondary to
alkali injury.
Clinical Relevance: Thalidomide may be used as a modulator of corneal angiogenesis to prolong graft
survival in eyes with pre-existing corneal neovascularization (JPMA 52:476;2002).
Introduction 
The first successfully transplanted solid tissue was the cornea1. The observation that corneas were less
frequently rejected compared to other tissues lead to the belief that the cornea enjoyed “Immunologic
Privilege”. This view is substantiated by the observation that vascularized and pre-sensitized recipients
reject comeal grafts more frequently than non-vascularized recipients2,3.
Cornea! graft rejection in uncomplicated cases occurs in about 3-35 % of the times. The incidence in
high-risk cases with inflammation and neovascularization increases to 40-65 %2,4. We were interested
in reducing this neovascularization so as to improve the chances of graft survival.
Thalidomide was developed in the 1950’s by Chemie-Grunenthal as a sedative and was so nontoxic in
rodents that an LD 50 could not be established. In 1961.
McBride5 and Lenz6 described an association between Thalidomide use in pregnant women and limb
defects in their babies. These teratogenic effects were reproduced in rabbits at 100-300 mg/kg/day7,8. It
has been postulated that the limb defects occurred as a result of the direct inhibitory effect of
Thalidomide on angiogenesis in the developing limb bud9,10. With this knowledge we chose rabbits for
our study. Thalidomide has been re-introduced into the US market for erythema nodosum leprosum and
the skin manifestations of lupus erythematosus.
In the past decade, there has been renewed interest in the antiangiogenic activity of this drug, especially
in Cancer research and Transplantation12,18.
Owing to its potent anti-angiogenic properties, Thalidomide would prevent or significantly retard the
growth of vessels into the donor cornea reducing the exposure of foreign tissue to the host defense
mechanisms, hence reducing the chances of rejection. D’Amato et al studied the effects of oral
Thalidomide on comeal angiogenesis, which they had experimentally produced in rabbit corneas using
basic fibroblast growth factor19. Their study demonstrated a significant inhibition of corneal
neovascularization in the Thalidomide group (200mg/kg/day). This antiangiogenic effect was observed
after only two doses and was comparable to the drug’s teratogenic properties. Later, Kruse et a! showed
the same effect when they induced comeal neovascularization with vascular endothelial growth factor
(VEGF)20.
This study evaluates the effects of Thalidomide in preventing neovascularization in corneal graft donor
buttons in rabbit eyes that have pre-existing neovascu!arization secondary to alkali burns.
Materials and Method 
Corneal neovascularization was induced in the left eye of sixteen male New Zealand white rabbits,
average weight 2.77 Kg. All animals were handled in accordance with the National Institute of Health
guidelines on the care
C/12 x 3.1416 - (r - L)2] where, r = radius of the cornea, C = number of clock hours of limbus involved
with neovascularization and L = Maximum vascular pedicle length from host-graft interface onto donor
cornea.
L = length of the longest vascular pedicle from the limbus onto anterior cornea.
The rabbits were then assigned randomly and in a double blinded manner to a test and a control group.
The test group had four and the control group, twelve rabbits. Penetrating keratoplasty was performed
on the vascularized left eye of fifteen rabbits, using an 8 mm corneal graft obtained from a healthy
rabbit, sutured into a 7.5 mm host interface, using sixteen to eighteen 10-0 nylon interrupted sutures.
Post-operatively, Tobramycin + Dexamethasone ointment was instilled and the eye was patched
overnight. Starting on post-operative day one, the four test rabbits were fed in a blinded fashion, 200
mg/Kg/day of Thalidomide for 30 days. The control group received placebo in the form of powdered
sugar. In addition, the eyes received Pred-forte 1% eye drops QID for 30 days and Ciprofloxacil HCL
eye drops QID tapered off over two weeks. Daily examinations were performed to assess the
development of infectious keratitis, corneal rejection, maintenance of cornea! clarity (Table 1) and the
development of corneal graft neovascularization. On day 30, an assessment of corneal
neovascularization was performed with the above mentioned equation, where r = Radius of the donor
cornea, (4.0 mm).
C = Number of clock hours of host-graft interface involved with neovascularization,
Following this, the rabbits were euthanized in accordance with the aforementioned guidelines. The
results were assimilated and the study unmasked. Data was entered and analyzed using the computer
software SPSS version 10.0 for Windows. Independent samples’ t-test was used to assess the efficacy
of Thalidomide in preventing neovascularization of the comeal graft.
Results 
Sixteen male New Zealand white rabbits, average weight 2.77 Kg suffered the initial alkali injury to
their left corneas and underwent the pre-operative recovery and neovascularization phase of four
weeks. During this preoperative (pre-thalidomide) recovery period, the control and the test groups did
not exhibit any clinically significant differences in the time of earliest detection of corneal
neovascularization, the number of clock hours (C) involved in the neo-vascular response, longest neo-
vascular pedicle length (L) from limbus onto anterior cornea, and the amount of total cornea! surface
area involved in neovascularization, (Table 1).
At the end of this period one rabbit was found to have a large central descemetocele and was removed
from the study, as the cornea was not transplantable. Fifteen rabbits thus underwent successful
penetrating keratoplasty. During the post-operative period, one rabbit developed severe keratitis and
endophthalmitis and was removed from the study. Both these rabbits belonged to the control group.
Fourteen rabbits completed the study (n14), (Table 1).
In the control group, earliest evidence of donor tissue neovascularization was detected significantly
earlier than the test group. The test group had significantly less clock hours (C) of donor corneal
circumference involved in neovascularization than the control group. The longest neovascular pedcle
length (L) was significantly shorter in the test group than in the control group. The total area of donor
cornea involved in neovascularization in the test group at the end of the study was significantly less
than the control group (Figures 1 and 2).


Table 2 describes the different grades of corneal opacity.
Table 3 demonstrates that all the rabbits reached grade I comeal opacification. However, the control
group required significantly fewer days to reach this level of corneal opacification compared to the test
group. All of the rabbits in the control group reached grade II and grade III. Seven often rabbits in the
control group developed grade IV opacification while none of the test rabbits progressed beyond grade
I (Figures 1 and 2).
Discussion 
The cornea is an immune privileged tissue that, when grafted orthotopically forms the anterior surface
of the immune privileged anterior chamber22, The factors responsible for this include presence of the
blood-aqueous barrier, the avascularity of the cornea, the absence of classic antigen-presenting cells
(APCs) in the central cornea, inhibitory factors in the aqueous humor, the phenomenon known as
anterior chamber-associated immune deviation (ACAID) and the intraocular expression of Fas ligand.
Loss of ocular immune privilege can occur with a breach in any or all of these mechanisms23,24. The
eyes are rendered high risk, at least in part, by virtue ofcomeal neovascularization failing to provide
immune privilege for orthotopic corneal allografts. Neovascularization creates graft beds in which
recipient antigen-presenting cells infiltrate the graft and carry antigenic information by lymphatics to
draining lymph nodes. In this manner, ACAID is avoided, and potentially allodestructive Delayed
Hypersensitivity is promoted25.
The cornea plays an active role in ocular immune privilege and ACAID by creating a local
immunosuppressive microenvironment, providing neural afferent stimuli that affect
immunosuppressive properties of Iris and Ciliary body, and preventing neovascularization and
infiltration with Langerhan’s cells26. Corneal endothelial cells inhibit antigen and mitogen-activated
lymphocyte proliferation27-29. Neuropeptides play also an important role in ocular immune privilege
and creation of an intraocular immunosuppressive microenvironment30-31.
The corneal graft contributes to its immune privileged status in three ways: (a) absence of donor-
derived, antigen-presenting passenger Langerhan’s cells in the comeal graft; (b) expression of Fas
ligand on the epithelium and endothelium of the corneal allograft and (c) capacity of the corneal
allograft to induce immune deviation of the systemic immune response32. Corneal allografts induce
cytotoxic T cell but not delayed hypersensitivity responses33. Apoptosis of infiltrating cells on the
corneal endothelium resulting from Fas-FasL interaction plays an important role in the high success
rate of comeal transplantation. Yamagami et al and Stuart et al showed that the rejection rate in the
FasL - group (89%) is significantly higher than in the FasL+ control group (47%)34-36
The donor-derived Langerhan’s cells act as Antigen Presenting Cells (APCs) in the induction of
delayed type hypersensitivity responsiveness to allergenic tissue37, The presence and persistence of
Langerhan’s cells in diseased corneas may account for, at least in part, a breakdown of comeal immune
privilege with a higher rate of rejection episodes after comeal transplantation38.
Thalidomide, after hydrolysis to active metabolites, specifically binds to GC promoters and inhibits
expression of ß2 and (33 integrin subunits by the leukocytes39-41. pzintegrins mediate leukocyte
adhesion to the endothelium. It also blocks the Vascular Endothelial Growth Factor (VEGF)-induced
down regulation of caveolin-1, vital for the propagation of endothelial cells20,42,43. In rat models,
Thalidomide has an immunosuppressive effect pronounced enough to replace corticosteroids after lung
transplantation13. It also upregulates the IL-4 and IL-5 expression, favoring TH2-type response over
TH 1-type response. In Cancer Research, it has also been shown to decrease Tumor Necrosis Factor -
alpha (TNF-ct) production by human monocytes, and raise Reactive Oxygen Species (ROS) levels44.
The results of this study clearly demonstrate the extreme effectiveness of thalidomide in decreasing the
rate of development of donor corneal neovascularization as manifested by later detection of donor
neovascularization compared to the control group. Also, Thalidomide reduces the severity of the total
neovascular response as shown by decreased number of clock hours (C) involved, decreased neo-
vascular pedicle length (L) from the host-donor interface onto donor cornea and decreased total donor
comeal surface area involved in the pannus. The study shows increased graft survival, with the test
group maintaining corneal clarity for a longer period of time as compared to the control group.
Oral Thalidomide, in conjunction with the present-day therapy for alkali bums, exceptionally retards
the development of and decreases the severity of neovascularization of donor comeal buttons in rabbit
eyes with pre-existing neovascularization secondary to previous alkali corneal burns. There is also a
marked increase in the longevity of functional graft tissue as evidenced by retained comeal clarity of
the donor tissue.
There might be some concern about the reproducibility of the induced corneal angiogenesis by our
injury model. However, this model has successfully been used in the past and our own pre-operative
findings (Table 2) indicate reproducible and consistent neovascularization induction. Thalidomide has
previously been shown to be effective in retarding neovascularization in both the FGF-ßand VEGF
models of induced comeal angiogenesis. We decided to assess the same in an alkali bum model as it
reflects real life scenarios experienced by clinicians. Even though our sample size is small, the results
are credible enough to be reported. Further studies need to be performed in order to assess the benefits
of continued use of Thalidomide as well as the ideal dosage.
If Thalidomide is ever considered for use as a corneal anti-angiogenic agent, its use will have to be
restricted to male patients and to women who are willing to perform at least two forms of
contraception, chemical and barrier, in addition to understanding the necessity of abortion if conception
were indeed to occur during Thalidomide use.
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